Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs Framework

AbundRX
Graded #181

Higher grade

vs+14.999999999999993
Framework
Graded #485

Lower grade

The verdict

AbundRX takes it — 66.6/100 to 51.6/100.

AbundRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AbundRX (Abundant Wellness) is an online medical weight-care platform connecting patients with licensed clinicians for compounded GLP-1 treatment.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAbundRX +22
67
45
Dose & formulationAbundRX +24
64
40
Clinical oversightAbundRX +7
79
72
Labs & monitoringAbundRX +1
53
52
FulfillmentAbundRX +17
74
57
Contract termsAbundRX +14
55
41
AbundRX · left barFramework · right bar

The numbers

MetricAbundRXFramework
WeighScore66.6/10051.6/100
GradeCC
Scorecard rank#181#485
Semaglutide$179/mo (compounded)Not disclosed
Tirzepatide$279/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AbundRX

Graded #181 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Framework

Graded #485 · C

Strengths

  • The compounding pharmacy partner is named, which most of this field does not do
  • Treatment selection is doctor-guided rather than a fixed product menu
  • US-licensed clinicians and a 503A pharmacy pathway

Where it loses points

  • No monthly medication price is published: the tirzepatide and semaglutide pages carry no price at all, and the homepage advertises a per-week figure for 'GLP-1s' generally rather than a rate for either drug
  • The only drug-specific prices anywhere on the site sit on a legacy page — semaglutide at $349 per three months and tirzepatide at $549 per three months
  • A '$75/month with 3-month package' figure is footnoted as a promotion for new GLP-1 users only
  • Different landing pages advertise different per-week rates, $25 on one and $19 on another
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard